Sphenopalatine Ganglion Block and Cold Induced Headaches

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-01

Study Completion Date

2025-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to determine if a sphenopalatine ganglion (SPG) block, performed through intranasal atomization of 4% lidocaine, is able to prevent cold induced cephalgia ("Brain Freeze"). Secondary objectives will be to determine the degree of decreased pain/duration of brain freeze after sphenopalatine ganglion block

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage

NCT07116408

Aneurysmal Subarachnoid Hemorrhage (aSAH) Headache

RECRUITING PHASE4

Sphenopalatine Ganglion Block for Headache After Concussion

NCT04650282

Concussion Headache

TERMINATED PHASE2

Efficacy of Percutaneous SPG Block in Aneurysmal SAH

NCT04331938

Subarachnoid Hemorrhage Headache

COMPLETED PHASE1

SGB in Management of Patients With PDPH Using TCD

NCT04401878

Post-Dural Puncture Headache

COMPLETED NA

Sphenopalatine Block in Headache in Patients With Non-traumatic Subarachnoid Hemorrhage

NCT06735261

Subarachnoid Hemorrhage in Adult Patients

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be performed in two phases. The first phase will include a pre-medicated phase where the subjects will be required to rapidly drink up to ½ of a 32 fluid oz icecold slushy to induce a brain freeze. The flavor will be chosen by the participants. The time to onset, intensity, location, and duration of the headache will be recorded. The second phase will commence when the subjects have returned to their normal pain free state, a minimum of 10 minutes has passed since the resolution of the first cold headache, and they feel ready to move to the next phase. The time from complete resolution of the brain freeze to the start of the second phase will be recorded. Any subject that wishes to drop out from the study at this time is free to do so. They may keep their drink and finish it at a more leisurely pace should they choose.

Then the subjects will receive either 1 mL of 4% lidocaine (0.5mL in each nostril) administered by intranasal atomization or 0.9% normal saline administered by intranasal atomization. The normal saline placebo will be mixed with an edible bittering agent added to blind the participant from recognizing the taste of the lidocaine containing solution.

Only participants that experienced a brain freeze in the first phase will be able to move onto the second phase. Each participant will then rapidly drink up to ½ of a 32 fluid oz ice-cold slushy to induce a brain freeze. The time to onset, intensity, location, and duration of the headache will be recorded.

All pain scores will be recorded using a visual analog scale from 0-100 where 0 is no pain and 100 is the worst pain imaginable. We will also record any side effects that the subjects may experience during or shortly after the procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cold Induced Headache Brain Freeze Cold Induced Cephalgia Headache

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

All besides PI

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Arm

Subjects will receive 1 mL of 4% lidocaine (0.5mL in each nostril) administered by intranasal atomization or 0.9% normal saline administered by intranasal atomization.

Group Type EXPERIMENTAL

Lidocaine Topical 4% Topical Solution

Intervention Type DRUG

Intranasal administration

Placebo Arm

Subjects will receive normal saline placebo mixed with an edible bittering agent added to blind the participant from recognizing the taste of the lidocaine containing solution.

Group Type PLACEBO_COMPARATOR

Bitrex

Intervention Type DRUG

Bittering agent

normal saline

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine Topical 4% Topical Solution

Intranasal administration

Intervention Type DRUG

Bitrex

Bittering agent

Intervention Type DRUG

normal saline

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Wright State University Emergency Medicine (EM) resident physicians and Wright State Boonshoft School of Medicine medical students
* Over the age of 18 years
* Has gotten at least one brain freeze in their life

Exclusion Criteria

* Individuals who have never gotten a brain freeze
* Anyone who has had any sort of prior trauma to their oro- or nasopharynx or surgery on their oro- or nasopharynx, not to include dental surgery.
* Pregnant patients
* History of allergy to local anesthetic

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes